Agranulocitosis secundaria a clozapinaa propósito de 2 casos
- Celia Canedo Magariños 1
- María Teresa Amboage Paz 1
- María José Recimil López 1
- Mario Páramo Fernández 1
- 1 Complejo Hospitalario Universitario de Santiago de Compostela
ISSN: 1134-5934
Year of publication: 2021
Volume: 28
Issue: 1
Pages: 38-42
Type: Article
More publications in: Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica
Sustainable development goals
Abstract
Clozapine is a gold standard in the treatment of refractory schizophrenia. The fear of the appearance and management of serious side effects, especially agranulocytosis, causes professionals not to use it frequently. This article describes a case of initiation of treatment with multiple clinical complications after the onset of neutropenia and a case of drug reexposure after a first attempt frustrated by agranulocytosis. In both cases, clozapine treatment had to be definitively withdrawn, but the patients full recovered. We believe that the presentation of cases in which relevant problems appeared c ould enrich the formation and inspire confidence among psychiatrist and residents in the management of similar cases.